company background image
SRPT logo

Sarepta Therapeutics NasdaqGS:SRPT Stock Report

Last Price

US$145.61

Market Cap

US$13.8b

7D

-4.3%

1Y

37.5%

Updated

21 Jul, 2024

Data

Company Financials +

Sarepta Therapeutics, Inc.

NasdaqGS:SRPT Stock Report

Market Cap: US$13.8b

SRPT Stock Overview

A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.

SRPT fundamental analysis
Snowflake Score
Valuation5/6
Future Growth6/6
Past Performance2/6
Financial Health3/6
Dividends0/6

Sarepta Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sarepta Therapeutics
Historical stock prices
Current Share PriceUS$145.61
52 Week HighUS$173.25
52 Week LowUS$55.25
Beta0.88
11 Month Change-9.40%
3 Month Change24.50%
1 Year Change37.54%
33 Year Change118.01%
5 Year Change-2.52%
Change since IPO273.36%

Recent News & Updates

Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Jul 05
Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Sarepta Therapeutics: Navigating Elevidys Upside Potential

Jun 17

Recent updates

Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Jul 05
Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Sarepta Therapeutics: Navigating Elevidys Upside Potential

Jun 17

Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear

May 08
Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear

Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

May 05
Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Apr 15
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

Apr 11

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Feb 06
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

Jan 22

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jan 10
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Dec 20
There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Nov 29
Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Aug 08
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Apr 30
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Jan 17
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001

Sep 29

Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027

Sep 12

Sarepta says FDA lifted clinical hold on Duchenne candidate

Sep 06

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Aug 22
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses

Aug 08

Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder

Jul 29

Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

May 09
Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

Sarepta: The DMD Leader

Apr 26

Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments

Feb 09

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Feb 07
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Dec 06
A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Shareholder Returns

SRPTUS BiotechsUS Market
7D-4.3%-0.1%-1.9%
1Y37.5%11.1%19.4%

Return vs Industry: SRPT exceeded the US Biotechs industry which returned 11.1% over the past year.

Return vs Market: SRPT exceeded the US Market which returned 19.4% over the past year.

Price Volatility

Is SRPT's price volatile compared to industry and market?
SRPT volatility
SRPT Average Weekly Movement10.3%
Biotechs Industry Average Movement10.7%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: SRPT has not had significant price volatility in the past 3 months.

Volatility Over Time: SRPT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19801,314Doug Ingramwww.sarepta.com

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.

Sarepta Therapeutics, Inc. Fundamentals Summary

How do Sarepta Therapeutics's earnings and revenue compare to its market cap?
SRPT fundamental statistics
Market capUS$13.76b
Earnings (TTM)US$16.90m
Revenue (TTM)US$1.40b

814.6x

P/E Ratio

9.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SRPT income statement (TTM)
RevenueUS$1.40b
Cost of RevenueUS$997.99m
Gross ProfitUS$405.31m
Other ExpensesUS$388.41m
EarningsUS$16.90m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.18
Gross Margin28.88%
Net Profit Margin1.20%
Debt/Equity Ratio128.9%

How did SRPT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.